CEO of Enzolytics IPF Immune: CRN Data Shows Record-Breaking Number of Americans Use Dietary Supplements

Eighty-percent of Americans are using dietary supplements according to initial data from the Council for Responsible Nutrition.

“The CRN data shows that not only are a record-number of Americans using dietary supplements as part of their regular health regimen, but they also increased their use of supplements that help boost their immune system,” said Charles S. Cotropia, CEO of Enzolytics, Inc., a biotech company based in Texas. “We are rolling out Enzolytics IPF Immune, an immune modulator that supports your immune system.”

Enzolytics IPF Immune debuted last week in front of buyers from large and small retail chains who attended ECRM’s “Weight Management, Nutrition, and Vitamin Program.”

“We have a dietary supplement that consumers want because of the pandemic,” Mr. Cotropia said. “The numbers support the consumer demand for immunity supplements, which is expected to grow from $20 billion in 2021 to more than $31 billion in 2028.”

“Enzolytics’ immune modulator supports immune function by positively supporting the immune system,” said Harry Zhabilov, CSO of Enzolytics, Inc. “We have devoted years to developing an immune modulator that fortifies your natural defenses.

“When you take Enzolytics IPF Immune, our product strengthens the body’s response against viruses or other pathogens,” Mr. Zhabilov added. “Enzolytics IPF Immune mitigates the damage that the viruses can do.”

Mr. Zhabilov said Enzolytics IPF Immune also minimizes the side effects following chemotherapy treatment.

“By using Enzolytics IPF Immune, you can also quicken the recovery period after completing chemotherapy,” he said.

Enzolytics IPF Immune is a gluten-free liquid supplement taken for two consecutive days per week, for eight consecutive weeks.

“Enzolytics’ research team brings more than four decades of experience in developing human health therapies,” Mr. Cotropia said. “We are a biotech company that concentrates on therapies, including Enzolytics IPF Immune, to treat various medical conditions.”

For more information, visit enzolytics.com.

Disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. This press release is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please check with your doctor. The news site hosting this press release is not associated with Enzolytics, Inc. It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the product or service.

About Enzolytics, Inc.

Enzolytics Inc. is a Texas-based biotechnology company that focuses on therapeutics to treat numerous human health medical conditions. In addition to Enzolytics IPF Immune, which will be on the U.S. market soon, the Company is developing other therapeutics for treating multiple infectious diseases.